Recent US and global policy developments (i.e., Joint Clinical Assessment, Inflation Reduction Act, FDA Data Requirements), evolving stakeholder expectations, and enhanced focus on sustained access have intensified manufacturer requirements for  demonstrating value. Against this landscape, life science companies need to evolve their value demonstration strategies to be successful in this dynamic environment. 

At ISPOR 2024 in Atlanta, Avalere Health presented the session, “No Longer Business as Usual: Establishing Value in an Uncertain and Dynamic Landscape,” which delved into methods for creating a coherent value strategy amidst this changing policy landscape. The article, published by The Evidence Base, provides a deep dive into the information shared during this session, including challenges and actionable strategies for life sciences companies.  

To read the full article, visit The Evidence Base.  

To learn more about how Avalere can assist you, connect with us.